Susan Galbraith, AstraZeneca EVP, oncology R&D
After nearly a decade of work, AstraZeneca axes WEE1 and culls Moderna-partnered drug
Nine years after doling out $50 million upfront to Merck, it appears AstraZeneca’s work in the WEE1 inhibitor space is over.
The UK Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
